John Vavricka serves as the Chief Commercial Officer at ATEA PHARMACEUTICALS INC, a biopharmaceutical company focused on developing novel therapeutics for viral infections. With a robust background in the pharmaceutical industry, John brings over two decades of experience in strategic planning, commercial operations, and business development. Prior to joining ATEA, he held significant roles at major pharmaceutical companies, including positions at Gilead Sciences and Merck & Co., where he was instrumental in the successful launch and commercialization of several high-profile antiviral drugs. At Gilead Sciences, John played a pivotal role in the global rollout of treatments for HIV and hepatitis C, significantly contributing to the company's market expansion and revenue growth. His strategic insights and leadership were key in navigating complex regulatory environments and forging partnerships that enhanced the company's portfolio. At Merck, he led the commercial team responsible for the launch of a groundbreaking antiviral therapy, which not only achieved substantial market penetration but also improved patient outcomes worldwide. As Chief Commercial Officer at ATEA PHARMACEUTICALS INC, John is responsible for overseeing the company's commercial strategy, including market analysis, product launches, and sales operations. His role is crucial in steering ATEA's efforts to bring innovative antiviral treatments to market efficiently and effectively. Under his leadership, ATEA aims to continue its mission of addressing unmet medical needs in the field of virology, leveraging John's extensive experience and proven track record to drive the company's growth and success.